Recent advances in NK cell translational research and clinical application in malignant diseases
We are glad to pronounce the third CellGenix Lecture given by Prof. Dr. Evelyn Ullrich. She will present recent results from translational NK cell research an give an overview on NK cell clinical studies. With our CellGenix Lectures we want to provide insights in the latest advances in the cell and gene therapy, and the regenerative medicine field.
"Recent advances in NK cell translational research and clinical application in malignant diseases"
Natural killer (NK) cells are a promising tool for the use in immunotherapy, since they efficiently recognize and kill tumor cells. For adoptive cell therapy, NK cells from different sources can be stimulated with cytokines and accessory or feeder cells. Clinical studies exploiting the impact of NK cells in the context of hematopoietic stem cell transplantation (HSCT) have provided promising results due to their antitumor capability supporting the graft-versus-leukemia effect (GVL) without causing graft-versus-host disease (GVHD) which is one of the most severe complications in allogeneic HSCT. Furthermore, remarkable advances have been made in the development of CAR NK cell technologies.
Prof. Dr. Evelyn Ullrich
Head of Cellular Immunology,
Department of Pediatric Stem Cell Transplantation and Immunology,
Johann Wolfgang Goethe-University, Frankfurt/Main
Thursday, April 27, 2017
17:00-18:00 p.m., followed by a drinks reception with pretzels and wine
Am Flughafen 16
79108 Freiburg, Germany
Please join us for the Inaugural Lecture and register for free via:
Lectures@cellgenix.com or T: 0761/88 88 9-0